{"protocolSection":{"identificationModule":{"nctId":"NCT01806675","orgStudyIdInfo":{"id":"IRB-25970"},"secondaryIdInfos":[{"id":"NCI-2013-00535","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"IRB-25970","type":"OTHER","domain":"Stanford IRB"},{"id":"VARIMG0002","type":"OTHER","domain":"OnCore ID"}],"organization":{"fullName":"Stanford University","class":"OTHER"},"briefTitle":"18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy","officialTitle":"Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis"},"statusModule":{"statusVerifiedDate":"2019-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-03-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-12-07","type":"ACTUAL"},"completionDateStruct":{"date":"2019-04","type":"ACTUAL"},"studyFirstSubmitDate":"2013-03-05","studyFirstSubmitQcDate":"2013-03-05","studyFirstPostDateStruct":{"date":"2013-03-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-08-14","resultsFirstSubmitQcDate":"2019-08-14","resultsFirstPostDateStruct":{"date":"2019-09-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-09-21","lastUpdatePostDateStruct":{"date":"2019-10-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Sanjiv Sam Gambhir","investigatorTitle":"Virginia and D.K. Ludwig Professor for Clinical Investigation in Cancer Research","investigatorAffiliation":"Stanford University"},"leadSponsor":{"name":"Sanjiv Sam Gambhir","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.","detailedDescription":"PRIMARY OBJECTIVE\n\n• Evaluate 18F-FPPRGD2 and 18F-FDG as PET/CT or PET/MRI radiotracers for imaging prediction and assessment of response to anti-angiogenesis therapy in participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC).\n\nSECONDARY OBJECTIVE\n\n• Progression-free survival (PFS) at up to 1 year after initial scans and treatment\n\nOUTLINE:\n\nPatients undergo 18F-FPPRGD2 and 18F-FDG PET/CT or PET/MRI medical imaging at baseline and at regular medical care follow-up (6 to 12 weeks).\n\nAfter completion of study imaging, patients are followed up at 12 months."},"conditionsModule":{"conditions":["Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Male Breast Cancer","Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Adult Brain Tumor","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Colon Cancer","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Hypopharyngeal Cancer","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Laryngeal Cancer","Recurrent Lip and Oral Cavity Cancer","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Nasopharyngeal Cancer","Recurrent Non-small Cell Lung Cancer","Recurrent Oropharyngeal Cancer","Recurrent Pancreatic Cancer","Recurrent Paranasal Sinus and Nasal Cavity Cancer","Recurrent Rectal Cancer","Recurrent Renal Cell Cancer","Recurrent Salivary Gland Cancer","Stage IIIA Breast Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Breast Cancer","Stage IIIB Non-small Cell Lung Cancer","Stage IIIC Breast Cancer","Stage IV Breast Cancer","Stage IV Non-small Cell Lung Cancer","Stage IV Pancreatic Cancer","Stage IV Renal Cell Cancer","Stage IVA Colon Cancer","Stage IVA Rectal Cancer","Stage IVA Salivary Gland Cancer","Stage IVB Colon Cancer","Stage IVB Salivary Gland Cancer","Stage IVC Salivary Gland Cancer","Tongue Cancer","Unspecified Adult Solid Tumor, Protocol Specific"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE","maskingDescription":"All human subject participants were to be evaluated with both 18F-FPPRGD2 PET/CT and 18-FDG PET/CT imaging scans."}},"enrollmentInfo":{"count":25,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Glioblastoma Multiforme (GBM)","type":"EXPERIMENTAL","description":"Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)","interventionNames":["Drug: 18F-fludeoxyglucose (18F-FDG)","Drug: 18F-FPPRGD2"]},{"label":"Gynecological Cancers","type":"EXPERIMENTAL","description":"Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)","interventionNames":["Drug: 18F-fludeoxyglucose (18F-FDG)","Drug: 18F-FPPRGD2"]},{"label":"Renal Cell Cancer (RCC)","type":"EXPERIMENTAL","description":"Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)","interventionNames":["Drug: 18F-fludeoxyglucose (18F-FDG)","Drug: 18F-FPPRGD2"]}],"interventions":[{"type":"DRUG","name":"18F-fludeoxyglucose (18F-FDG)","description":"18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan","armGroupLabels":["Glioblastoma Multiforme (GBM)","Gynecological Cancers","Renal Cell Cancer (RCC)"],"otherNames":["Fludeoxyglucose F-18","18-FDG","FDG"]},{"type":"DRUG","name":"18F-FPPRGD2","description":"18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.","armGroupLabels":["Glioblastoma Multiforme (GBM)","Gynecological Cancers","Renal Cell Cancer (RCC)"],"otherNames":["(18F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid peptide","[PEG3-E{c(RGDyk)}2]","fluorine-18-FPPRGD2","[18F]-FPPRGD2","2-fluoropropionyl-labeled pegylated dimeric RGD peptide","104150"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Maximum Standard Uptake Values (SUVmax)","description":"Maximum standard uptake values (SUVmax) were assessed on the basis of position emission tomography (PET) scans using radiotracers 18F-FPPRGD2 and 18F-FDG at baseline and at regular medical care follow-up (6 to 12 weeks after initiation of treatment). The outcome is assessed as the difference in the maximum standard uptake values (SUVmax) values from baseline to follow-up for the 2 radiotracers, and will be reported for each disease type as the median with standard deviation.","timeFrame":"At baseline and 6 weeks"}],"secondaryOutcomes":[{"measure":"Response Assessment by RANO Criteria","description":"The treatment effect for participants with glioblastoma multiforme was to be assessed on the basis of post-treatment evaluation per the Response Assessment in Neuro-Oncology (RANO) Criteria. The outcome was the number \\& proportion of participants that achieved either a complete response (CR) or partial response (PR), a number without dispersion. RANO criteria are:\n\nCR= No T1 gadolinium (T1-G); T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) stable/decreased, no new lesions; no corticosteroids; clinical condition improved/stable.\n\nPR= ≥50% decrease in T1-G; T2/FLAIR decreased/stable ; no new lesions; decreased/stable corticosteroids; clinical condition improved/stable.\n\nStable disease (SD)= \\<50% decrease, but more than 25% increase, in T1-G; T2/FLAIR decreased/stable; no new lesions; decreased/stable corticosteroids; clinical condition improved/stable.\n\nProgressive disease (PD)= ≥25%increase T1-G; T2/FLAIR increased; increased corticosteroids; clinical condition decreased","timeFrame":"At baseline and 6 weeks"},{"measure":"Change in Tumor Size","description":"The treatment effect for participants with gynecological cancers (GYN) and renal cell carcinoma (RCC) was assessed on the basis of change in tumor size as determined by pre- and post-treatment CT scans. The outcome is reported as the difference at treatment follow-up, reported as the median with standard deviation.","timeFrame":"9 to 12 weeks"},{"measure":"Tumor Response Rate by EORTC Criteria","description":"Tumor Response Rate by EORTC Criteria Tumor response rates were assessed from position emission tomography (PET) scans using 18F-FPPRGD2 \\& 18F-FDG at baseline \\& after 6 weeks of treatment, per European Organization for Research \\& Treatment of Cancer (EORTC) response criteria. The outcome is reported for each radiotracer by disease group as the number of participants achieving complete response (CR), partial response (PR), stable disease (SD), \\& progressive disease (PD).\n\n* CR= complete resolution of 18F-FDG uptake tumor volume\n* PR= reduction of 15-25% in tumor 18F-FDG SUVmax after 1 cycle of chemotherapy, and ≥25% after \\>1 cycle\n* SD= increase in tumor 18F-FDG SUVmax of \\<25% or a decrease of \\<15% \\& no increase in 18F-FDG tumor uptake \\[\\>20% in the longest dimension (LD)\\];\n* PD= increase in 18F-FDG tumor SUVmax of \\>25% in tumor region on baseline; increase in extent of 18F-FDG tumor uptake (\\>20% in LD); appearance of new 18F-FDG uptake in metastatic lesions","timeFrame":"At baseline and 6 weeks"},{"measure":"Progression-free Survival (PFS)","description":"Progression-free survival (PFS) was defined as remaining alive at 1 year with disease progression, according to the physician's assessment of clinical status, by disease group.","timeFrame":"1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provides written informed consent\n* Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis treatment or treatment with other drugs that may alter angiogenesis\n* Able to remain still for duration of each imaging procedure (about one hour)\n\nExclusion Criteria:\n\n* Pregnant or nursing\n* Contraindication to MRI\n* History of renal insufficiency (only for MRI contrast administration)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Sanjiv Gambhir, MD, PhD","affiliation":"Stanford University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Stanford University, School of Medicine","city":"Stanford","state":"California","zip":"94305","country":"United States","geoPoint":{"lat":37.42411,"lon":-122.16608}}]},"referencesModule":{"references":[{"pmid":"26062933","type":"RESULT","citation":"Minamimoto R, Jamali M, Barkhodari A, Mosci C, Mittra E, Shen B, Chin F, Gambhir SS, Iagaru A. Biodistribution of the (1)(8)F-FPPRGD(2) PET radiopharmaceutical in cancer patients: an atlas of SUV measurements. Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1850-8. doi: 10.1007/s00259-015-3096-4. Epub 2015 Jun 11."},{"pmid":"25965900","type":"RESULT","citation":"Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, Li G, Nagpal S, Recht L, Gambhir SS. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT. Radiology. 2015 Nov;277(2):497-506. doi: 10.1148/radiol.2015141550. Epub 2015 May 12."},{"pmid":"26611425","type":"RESULT","citation":"Minamimoto R, Karam A, Jamali M, Barkhodari A, Gambhir SS, Dorigo O, Iagaru A. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1047-55. doi: 10.1007/s00259-015-3263-7. Epub 2015 Nov 27."},{"pmid":"30850872","type":"RESULT","citation":"Toriihara A, Duan H, Thompson HM, Park S, Hatami N, Baratto L, Fan AC, Iagaru A. 18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer. Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1518-1523. doi: 10.1007/s00259-019-04295-7. Epub 2019 Mar 8."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Glioblastoma Multiforme (GBM)","description":"Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"FG001","title":"Gynecological Cancers","description":"Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"FG002","title":"Renal Cell Cancer (RCC)","description":"Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"8"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Glioblastoma Multiforme (GBM)","description":"Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"BG001","title":"Gynecological Cancers","description":"Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"BG002","title":"Renal Cell Cancer (RCC)","description":"Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"25"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"21"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"4"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54.1","spread":"8.3"},{"groupId":"BG001","value":"44.3","spread":"12.6"},{"groupId":"BG002","value":"64.1","spread":"13.3"},{"groupId":"BG003","value":"54.9","spread":"13.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"14"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"11"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"22"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"14"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"25"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Maximum Standard Uptake Values (SUVmax)","description":"Maximum standard uptake values (SUVmax) were assessed on the basis of position emission tomography (PET) scans using radiotracers 18F-FPPRGD2 and 18F-FDG at baseline and at regular medical care follow-up (6 to 12 weeks after initiation of treatment). The outcome is assessed as the difference in the maximum standard uptake values (SUVmax) values from baseline to follow-up for the 2 radiotracers, and will be reported for each disease type as the median with standard deviation.","populationDescription":"Some participants did not contribute some or all post-treatment scans.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Standard Deviation","unitOfMeasure":"ratio","timeFrame":"At baseline and 6 weeks","groups":[{"id":"OG000","title":"Glioblastoma Multiforme (GBM)","description":"Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"OG001","title":"Gynecological Cancers","description":"Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"OG002","title":"Renal Cell Cancer (RCC)","description":"Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}],"classes":[{"title":"18F-FPPRGD2 PET scans","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.98","spread":"0.98"},{"groupId":"OG001","value":"0.09","spread":"1.20"},{"groupId":"OG002","value":"0.10","spread":"0.29"}]}]},{"title":"18F-FDG PET scans","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-1.90","spread":"2.80"},{"groupId":"OG002","value":"7.8","spread":"8.2"}]}]}]},{"type":"SECONDARY","title":"Response Assessment by RANO Criteria","description":"The treatment effect for participants with glioblastoma multiforme was to be assessed on the basis of post-treatment evaluation per the Response Assessment in Neuro-Oncology (RANO) Criteria. The outcome was the number \\& proportion of participants that achieved either a complete response (CR) or partial response (PR), a number without dispersion. RANO criteria are:\n\nCR= No T1 gadolinium (T1-G); T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) stable/decreased, no new lesions; no corticosteroids; clinical condition improved/stable.\n\nPR= ≥50% decrease in T1-G; T2/FLAIR decreased/stable ; no new lesions; decreased/stable corticosteroids; clinical condition improved/stable.\n\nStable disease (SD)= \\<50% decrease, but more than 25% increase, in T1-G; T2/FLAIR decreased/stable; no new lesions; decreased/stable corticosteroids; clinical condition improved/stable.\n\nProgressive disease (PD)= ≥25%increase T1-G; T2/FLAIR increased; increased corticosteroids; clinical condition decreased","populationDescription":"This assessment was restricted to glioblastoma multiforme (GBM) participants only, however, no response assessments were obtained for GBM participants.","reportingStatus":"POSTED","timeFrame":"At baseline and 6 weeks","groups":[{"id":"OG000","title":"Glioblastoma Multiforme (GBM)","description":"Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"OG001","title":"Gynecological Cancers","description":"Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"OG002","title":"Renal Cell Cancer (RCC)","description":"Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"type":"SECONDARY","title":"Change in Tumor Size","description":"The treatment effect for participants with gynecological cancers (GYN) and renal cell carcinoma (RCC) was assessed on the basis of change in tumor size as determined by pre- and post-treatment CT scans. The outcome is reported as the difference at treatment follow-up, reported as the median with standard deviation.","populationDescription":"This assessment was restricted to gynecological cancers and renal cell carcinoma participants only. Tumor response data was not available for all participants in these groups.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Standard Deviation","unitOfMeasure":"centimeters","timeFrame":"9 to 12 weeks","groups":[{"id":"OG000","title":"Glioblastoma Multiforme (GBM)","description":"Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"OG001","title":"Gynecological Cancers","description":"Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"OG002","title":"Renal Cell Cancer (RCC)","description":"Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0.9","spread":"1.56"},{"groupId":"OG002","value":"1","spread":"1.56"}]}]}]},{"type":"SECONDARY","title":"Tumor Response Rate by EORTC Criteria","description":"Tumor Response Rate by EORTC Criteria Tumor response rates were assessed from position emission tomography (PET) scans using 18F-FPPRGD2 \\& 18F-FDG at baseline \\& after 6 weeks of treatment, per European Organization for Research \\& Treatment of Cancer (EORTC) response criteria. The outcome is reported for each radiotracer by disease group as the number of participants achieving complete response (CR), partial response (PR), stable disease (SD), \\& progressive disease (PD).\n\n* CR= complete resolution of 18F-FDG uptake tumor volume\n* PR= reduction of 15-25% in tumor 18F-FDG SUVmax after 1 cycle of chemotherapy, and ≥25% after \\>1 cycle\n* SD= increase in tumor 18F-FDG SUVmax of \\<25% or a decrease of \\<15% \\& no increase in 18F-FDG tumor uptake \\[\\>20% in the longest dimension (LD)\\];\n* PD= increase in 18F-FDG tumor SUVmax of \\>25% in tumor region on baseline; increase in extent of 18F-FDG tumor uptake (\\>20% in LD); appearance of new 18F-FDG uptake in metastatic lesions","populationDescription":"This assessment was restricted to gynecological cancers and renal cell carcinoma participants only. Tumor response data was not available for all participants in these groups.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"At baseline and 6 weeks","groups":[{"id":"OG000","title":"Glioblastoma Multiforme (GBM)","description":"Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"OG001","title":"Gynecological Cancers","description":"Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"OG002","title":"Renal Cell Cancer (RCC)","description":"Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}],"classes":[{"title":"Complete Response (CR)","categories":[{"measurements":[{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Partial Repsonse (PR)","categories":[{"measurements":[{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Stable Disease (SD)","categories":[{"measurements":[{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]},{"title":"Progressive Disease","categories":[{"measurements":[{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"Progression-free survival (PFS) was defined as remaining alive at 1 year with disease progression, according to the physician's assessment of clinical status, by disease group.","populationDescription":"Data was not collected for progression-free survival (PFS).","reportingStatus":"POSTED","timeFrame":"1 year","groups":[{"id":"OG000","title":"Glioblastoma Multiforme (GBM)","description":"Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"OG001","title":"Gynecological Cancers","description":"Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."},{"id":"OG002","title":"Renal Cell Cancer (RCC)","description":"Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"6 weeks","eventGroups":[{"id":"EG000","title":"Glioblastoma Multiforme (GBM)","description":"Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.","deathsNumAffected":1,"deathsNumAtRisk":11,"seriousNumAffected":1,"seriousNumAtRisk":11,"otherNumAffected":0,"otherNumAtRisk":11},{"id":"EG001","title":"Gynecological Cancers","description":"Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":0,"otherNumAtRisk":6},{"id":"EG002","title":"Renal Cell Cancer (RCC)","description":"Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":2,"seriousNumAtRisk":8,"otherNumAffected":0,"otherNumAtRisk":8}],"seriousEvents":[{"term":"Death NOS","organSystem":"General disorders","sourceVocabulary":"CTCAE v (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE V (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":8}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Sanjiv Sam Gambhir, Professor for Clinical Investigation in Cancer Research and Professor","organization":"Stanford University","email":"sgambhir@stanford.edu","phone":"650-725-6175"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D005909","term":"Glioblastoma"},{"id":"D018316","term":"Gliosarcoma"},{"id":"D018567","term":"Breast Neoplasms, Male"},{"id":"D001932","term":"Brain Neoplasms"},{"id":"D003110","term":"Colonic Neoplasms"},{"id":"D018304","term":"Esthesioneuroblastoma, Olfactory"},{"id":"D007012","term":"Hypopharyngeal Neoplasms"},{"id":"D007822","term":"Laryngeal Neoplasms"},{"id":"D009062","term":"Mouth Neoplasms"},{"id":"D009303","term":"Nasopharyngeal Neoplasms"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D009959","term":"Oropharyngeal Neoplasms"},{"id":"D010190","term":"Pancreatic Neoplasms"},{"id":"D012004","term":"Rectal Neoplasms"},{"id":"D002292","term":"Carcinoma, Renal Cell"},{"id":"D012468","term":"Salivary Gland Neoplasms"},{"id":"D001943","term":"Breast Neoplasms"},{"id":"D014062","term":"Tongue Neoplasms"}],"ancestors":[{"id":"D001254","term":"Astrocytoma"},{"id":"D005910","term":"Glioma"},{"id":"D018302","term":"Neoplasms, Neuroepithelial"},{"id":"D017599","term":"Neuroectodermal Tumors"},{"id":"D009373","term":"Neoplasms, Germ Cell and Embryonal"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009380","term":"Neoplasms, Nerve Tissue"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D016543","term":"Central Nervous System Neoplasms"},{"id":"D009423","term":"Nervous System Neoplasms"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D015179","term":"Colorectal Neoplasms"},{"id":"D007414","term":"Intestinal Neoplasms"},{"id":"D005770","term":"Gastrointestinal Neoplasms"},{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D003108","term":"Colonic Diseases"},{"id":"D007410","term":"Intestinal Diseases"},{"id":"D009447","term":"Neuroblastoma"},{"id":"D018241","term":"Neuroectodermal Tumors, Primitive, Peripheral"},{"id":"D018242","term":"Neuroectodermal Tumors, Primitive"},{"id":"D020431","term":"Olfactory Nerve Diseases"},{"id":"D003389","term":"Cranial Nerve Diseases"},{"id":"D010610","term":"Pharyngeal Neoplasms"},{"id":"D010039","term":"Otorhinolaryngologic Neoplasms"},{"id":"D006258","term":"Head and Neck Neoplasms"},{"id":"D010608","term":"Pharyngeal Diseases"},{"id":"D009057","term":"Stomatognathic Diseases"},{"id":"D010038","term":"Otorhinolaryngologic Diseases"},{"id":"D007818","term":"Laryngeal Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D009059","term":"Mouth Diseases"},{"id":"D009302","term":"Nasopharyngeal Diseases"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D004701","term":"Endocrine Gland Neoplasms"},{"id":"D010182","term":"Pancreatic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D012002","term":"Rectal Diseases"},{"id":"D000230","term":"Adenocarcinoma"},{"id":"D002277","term":"Carcinoma"},{"id":"D007680","term":"Kidney Neoplasms"},{"id":"D014571","term":"Urologic Neoplasms"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D007674","term":"Kidney Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D012466","term":"Salivary Gland Diseases"},{"id":"D014060","term":"Tongue Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D019788","term":"Fluorodeoxyglucose F18"},{"id":"C574086","term":"FPP(RGD)2"}],"ancestors":[{"id":"D003847","term":"Deoxyglucose"},{"id":"D003837","term":"Deoxy Sugars"},{"id":"D002241","term":"Carbohydrates"}]}},"hasResults":true}